Narizenta Duo Tablet 2.5/1000 mg
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Pharmgen Science Co., Ltd.
MFDS item code 202201811 · Approved 2022.05.03
Improves glycemic control in type 2 diabetes mellitus
This medication helps patients with type 2 diabetes to effectively control blood sugar levels in conjunction with diet and exercise. It is used to improve blood sugar levels by combining linagliptin and metformin.
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug treatment in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this medication should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered in combination with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see Precautions for Use, 3. Administration with Caution in the Following Patients). Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do Not Administer to the Following Patients).
This medication can cause a rare but very serious side effect known as lactic acidosis, which requires careful attention. The risk of lactic acidosis is higher when there is a rapid decline in kidney function or issues with heart or lung function. This medication should not be administered to certain patients, such as those who are allergic to its components, those with type 1 diabetes, lactic acidosis, severe renal impairment, acute infections, heart failure, liver dysfunction, acute alcohol intoxication, or during pregnancy. Additionally, there is a risk of hypoglycemia, so blood sugar levels should be closely monitored when taken with hypoglycemic agents like sulfonylureas or insulin. Excessive exercise, inadequate meals, and alcohol consumption may also increase the risk of hypoglycemia. Patients with weakened kidney function or the elderly should undergo regular kidney function tests before and during the use of this medication, and it should not be used if kidney function declines significantly. Patients with unstable heart function or acute heart failure should use this medication with caution, and it should be temporarily stopped before and after the administration of iodine contrast used in radiological examinations. While taking this medication, skin conditions such as acute pancreatitis or bullous pemphigoid may occur; therefore, if severe abdominal pain or blisters on the skin arise, notify a doctor immediately. Long-term use may result in vitamin B12 deficiency; hence, if symptoms of anemia or neurological issues develop, vitamin B12 levels should be checked and supplementation may be necessary. Women who are pregnant or breastfeeding should avoid this medication, and it is not recommended for children under 10 years old or adolescents. This medication may interact with other drugs; therefore, caution is warranted, especially when taken with drugs that affect renal function, hypoglycemic agents, or alcohol. In case of overdose, there is an increased risk of lactic acidosis, and immediate medical treatment should be sought, which may include blood dialysis. Store this medication out of the reach of children, avoid moisture, and it is advisable not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture; therefore, it should be stored in a tightly closed container. It is also advised to store it at room temperature, ideally between 1 degree and 30 degrees Celsius, to maintain its effectiveness for a prolonged period.
Bright pink, bilaterally convex, oval-shaped film-coated tablets
60 tablets/Alu-Alu [60 tablets (10 tablets/Alu-Alu x6)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Pharmgen Science Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.